Novo Nordisk record profits with weight-loss-drug demand boost

CGTN Europe 2023-11-02

Views 2

Fiona Cincotta, Analyst from City Index talks with CGTN Europe on Novo Nordisk Q3 result.
Show more

Share This Video


Download

  
Report form
RELATED VIDEOS
Novo Nordisk reports Q1 profits o $3.65 BN as demand for weightloss drug soars
play
04:15

Novo Nordisk reports Q1 profits o $3.65 BN as demand for weightloss drug soars
Novo Nordisk cuts supply of obesity drug Wegovy in the US due to surging demand
play
00:45

Novo Nordisk cuts supply of obesity drug Wegovy in the US due to surging demand
Ten Pharma Firms Form Non-profit to Speed Up New Drug Trials; InBalance Health Launches New Nutrition Bars; Novo Nordisk Ranks High on Carbon Disclosure Project - Health Minute for September 27, 2012
play
01:52

Ten Pharma Firms Form Non-profit to Speed Up New Drug Trials; InBalance Health Launches New Nutrition Bars; Novo Nordisk Ranks High on Carbon Disclosure Project - Health Minute for September 27, 2012
Novo Nordisk Shares Pop as New Obesity Drug Candidate Shows Impressive 13.1% Weight Loss in Early Trials
play
00:39

Novo Nordisk Shares Pop as New Obesity Drug Candidate Shows Impressive 13.1% Weight Loss in Early Trials
Novo Nordisk earnings: sales of weight-loss drug Wegovy lower than expected
play
03:24

Novo Nordisk earnings: sales of weight-loss drug Wegovy lower than expected
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
play
01:00

Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
Streetsmart Marketing Testimonial - From Loss Profits to increase Profits
play
03:37

Streetsmart Marketing Testimonial - From Loss Profits to increase Profits
Novo Nordisk Boosts 2023 Outlook
play
00:49

Novo Nordisk Boosts 2023 Outlook
Novo Nordisk Raises Sales Growth Outlook Despite Profit Miss. CEO Predicts 'Attractive Growth' Amidst Competition and Regulation Shifts.
play
00:35

Novo Nordisk Raises Sales Growth Outlook Despite Profit Miss. CEO Predicts 'Attractive Growth' Amidst Competition and Regulation Shifts.
Weight Loss Bubble? Investors Bullish on Novo Nordisk and Eli Lilly as Obesity Epidemic Drives Sales of Ozempic and Wegovy
play
00:42

Weight Loss Bubble? Investors Bullish on Novo Nordisk and Eli Lilly as Obesity Epidemic Drives Sales of Ozempic and Wegovy
Wegovy heart benefits due to more than weight loss -Novo Nordisk
play
01:32

Wegovy heart benefits due to more than weight loss -Novo Nordisk
Mantis Tiller boosted profits by boosting its guarantee
play
03:31

Mantis Tiller boosted profits by boosting its guarantee